yervoy-navigation-1-jl

The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Phase 1/2 SYLT-023 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in patients with advanced, HER2-negative, mismatch repair–proficient gastric/GEJ cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Adding trastuzumab and pertuzumab to chemotherapy conferred higher toxicity among patients with HER2-positive gastric cancers in the INNOVATION trial.

Results from the CheckMate 649 trial showed continued efficacy at 5 years in the nivolumab combination for patients with gastric/GEJ/esophageal cancer.